HC Wainwright Estimates NovoCure's Q2 Earnings (NASDAQ:NVCR)

Key Points

• HC Wainwright raised near‑term EPS forecasts for NovoCure—Q2 2026 EPS was revised to ($0.23) from ($0.28)—and reiterated a Buy rating with a $49 price target.
• At the same time, HC Wainwright materially lowered medium‑ and long‑term estimates (FY2026 ($1.26), FY2027 ($1.07), FY2028 $0.17, FY2029 $2.07, FY2030 $4.31), signaling weaker longer‑term profitability expectations.
• NovoCure missed on EPS in the latest quarter (reported ($0.62) vs. ($0.51) expected) but beat revenue at $174.06 million (+12.3% YoY); the stock trades near $16.93 and the analyst consensus is a Hold with a $27.29 target.

NovoCure Limited (NASDAQ:NVCR - Free Report) - Analysts at HC Wainwright raised their Q2 2026 earnings per share estimates for shares of NovoCure in a report issued on Thursday, April 30th. HC Wainwright analyst E. Bodnar now expects that the medical equipment provider will post earnings of ($0.23) per share for the quarter, up from their prior forecast of ($0.28). HC Wainwright has a "Buy" rating and a $49.00 price objective on the stock. The consensus estimate for NovoCure's current full-year earnings is ($1.51) per share. HC Wainwright also issued estimates for NovoCure's Q3 2026 earnings at ($0.22) EPS, Q4 2026 earnings at ($0.19) EPS, FY2026 earnings at ($1.26) EPS, FY2027 earnings at ($1.07) EPS, FY2028 earnings at $0.17 EPS, FY2029 earnings at $2.07 EPS and FY2030 earnings at $4.31 EPS.

A number of other analysts also recently issued reports on the company. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of NovoCure in a research note on Tuesday, April 21st. Evercore reaffirmed an "outperform" rating on shares of NovoCure in a research note on Friday. Wedbush reaffirmed a "neutral" rating and issued a $18.00 price objective on shares of NovoCure in a research note on Thursday, April 16th. Finally, Wells Fargo & Company lifted their price objective on NovoCure from $13.50 to $17.00 and gave the stock an "equal weight" rating in a research note on Monday. Four analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $27.29.

NovoCure Stock Performance

NASDAQ:NVCR opened at $16.93 on Tuesday. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.90 and a quick ratio of 2.71. NovoCure has a 1 year low of $9.82 and a 1 year high of $20.06. The stock's 50 day simple moving average is $12.11 and its two-hundred day simple moving average is $12.44. The company has a market cap of $1.96 billion, a price-to-earnings ratio of -11.07 and a beta of 0.90.

NovoCure (NASDAQ:NVCR - Get Free Report) last released its quarterly earnings data on Thursday, April 30th. The medical equipment provider reported ($0.62) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.11). NovoCure had a negative return on equity of 50.34% and a negative net margin of 25.66%.The firm had revenue of $174.06 million during the quarter, compared to the consensus estimate of $167.77 million. During the same period in the previous year, the firm earned ($0.31) EPS. The business's revenue was up 12.3% compared to the same quarter last year.

Hedge Funds Weigh In On NovoCure

Several hedge funds have recently bought and sold shares of NVCR. AQR Capital Management LLC grew its position in NovoCure by 56.7% in the 1st quarter. AQR Capital Management LLC now owns 28,728 shares of the medical equipment provider's stock valued at $512,000 after acquiring an additional 10,394 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of NovoCure by 3.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 74,992 shares of the medical equipment provider's stock worth $1,336,000 after buying an additional 2,502 shares during the period. Goldman Sachs Group Inc. lifted its holdings in shares of NovoCure by 5.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 993,670 shares of the medical equipment provider's stock worth $17,707,000 after buying an additional 52,180 shares during the period. Acadian Asset Management LLC purchased a new stake in shares of NovoCure in the 1st quarter worth $87,000. Finally, Prudential Financial Inc. purchased a new stake in shares of NovoCure in the 2nd quarter worth $216,000. Institutional investors own 84.61% of the company's stock.

Insider Activity

In other NovoCure news, CEO Frank X. Leonard sold 5,607 shares of the company's stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $13.31, for a total value of $74,629.17. Following the transaction, the chief executive officer owned 493,793 shares of the company's stock, valued at $6,572,384.83. This represents a 1.12% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, COO Mukund Paravasthu sold 43,246 shares of the company's stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $13.77, for a total value of $595,497.42. Following the completion of the transaction, the chief operating officer directly owned 72,832 shares in the company, valued at $1,002,896.64. This trade represents a 37.26% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 140,041 shares of company stock worth $1,860,116. Company insiders own 5.52% of the company's stock.

More NovoCure News

Here are the key news stories impacting NovoCure this week:

• Positive Sentiment: HC Wainwright raised near‑term EPS forecasts (Q2–Q4 2026) — analyst E. Bodnar trimmed losses for upcoming quarters (Q2 to ($0.23), Q3 to ($0.22), Q4 to ($0.19)), signaling slightly better near‑term profitability expectations; HC Wainwright still maintains a "Buy" rating and a $49 target. MarketBeat NVCR coverage
• Neutral Sentiment: Wells Fargo raised its price target to $17.00 and kept an "Equal Weight" rating — a modest upside tweak that gives near‑term technical/price support but is not a strong bullish endorsement. Benzinga article
• Neutral Sentiment: Media coverage highlights improving relative price strength and a Zacks deep‑dive on NovoCure’s international revenue trends — useful context for growth expectations but not an immediate catalyst. MSN piece Zacks deep dive
• Negative Sentiment: HC Wainwright cut medium‑ and long‑term EPS estimates substantially (FY2026 → ($1.26), FY2027 → ($1.07), FY2028 → $0.17, FY2029 → $2.07, FY2030 → $4.31 from higher prior figures), reflecting weaker longer‑term profitability assumptions and lowering forward earnings visibility despite the Buy rating. MarketBeat NVCR coverage

NovoCure Company Profile

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company's non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure's approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.